Finanzen von Retractable Technologies Inc (RVP)RVPRetractable Technologies Inc

Retractable Technologies Inc (RVP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Syringes, accounting for 80.8% of total sales, equivalent to $5.80M. Other significant revenue streams include EasyPoint Needles and Blood Cllection Products. Understanding this composition is critical for investors evaluating how RVP navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Retractable Technologies Inc maintains a gross margin of 90.85%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 37.13%, while the net margin is 39.31%. These profitability ratios, combined with a Return on Equity (ROE) of -4.83%, provide a clear picture of how effectively RVP converts its operational activities into shareholder value.

In the context of the broader market, RVP competes directly with industry leaders such as LFWD and CTSO. With a market capitalization of $20.73M, it holds a significant position in the sector. When comparing efficiency, RVP's gross margin of 90.85% stands against LFWD's 40.90% and CTSO's 73.18%. Such benchmarking helps identify whether Retractable Technologies Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue with total revenue of 7.2 million in Q1 2026, down from previous periods, and a gross margin that has recently improved significantly to 90.85%.